vs
Side-by-side financial comparison of CRA INTERNATIONAL, INC. (CRAI) and IDEAYA Biosciences, Inc. (IDYA). Click either name above to swap in a different company.
IDEAYA Biosciences, Inc. is the larger business by last-quarter revenue ($207.8M vs $197.0M, roughly 1.1× CRA INTERNATIONAL, INC.). IDEAYA Biosciences, Inc. runs the higher net margin — 57.4% vs 6.7%, a 50.7% gap on every dollar of revenue.
CRA INTERNATIONAL, INC.CRAIEarnings & Financial Report
CRA International, Inc. is a global consulting firm headquartered in Boston. The firm provides expert testimony and litigation support, strategic advice, and analysis to law firms, corporations, accounting firms, and governments.
IDEAYA Biosciences, Inc. is a clinical-stage biotechnology company focused on oncology, developing targeted therapies and synthetic lethality treatments for patients with genetically defined cancers. It advances a pipeline of candidates across multiple tumor types, partnering with industry stakeholders to accelerate global access to innovative cancer care solutions.
CRAI vs IDYA — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $197.0M | $207.8M |
| Net Profit | $13.2M | $119.2M |
| Gross Margin | — | — |
| Operating Margin | 10.5% | 52.2% |
| Net Margin | 6.7% | 57.4% |
| Revenue YoY | 11.6% | — |
| Net Profit YoY | -12.0% | 330.1% |
| EPS (diluted) | $1.99 | $1.33 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $197.0M | — | ||
| Q3 25 | $185.9M | $207.8M | ||
| Q2 25 | $186.9M | — | ||
| Q1 25 | $181.9M | — | ||
| Q4 24 | $176.4M | — | ||
| Q3 24 | $167.7M | $0 | ||
| Q2 24 | $171.4M | $0 | ||
| Q1 24 | $171.8M | $0 |
| Q4 25 | $13.2M | — | ||
| Q3 25 | $11.5M | $119.2M | ||
| Q2 25 | $12.1M | — | ||
| Q1 25 | $18.0M | — | ||
| Q4 24 | $15.0M | — | ||
| Q3 24 | $11.4M | $-51.8M | ||
| Q2 24 | $6.5M | $-52.8M | ||
| Q1 24 | $13.7M | $-39.6M |
| Q4 25 | 10.5% | — | ||
| Q3 25 | 9.3% | 52.2% | ||
| Q2 25 | 10.6% | — | ||
| Q1 25 | 14.0% | — | ||
| Q4 24 | 12.2% | — | ||
| Q3 24 | 11.0% | — | ||
| Q2 24 | 6.6% | — | ||
| Q1 24 | 11.4% | — |
| Q4 25 | 6.7% | — | ||
| Q3 25 | 6.2% | 57.4% | ||
| Q2 25 | 6.5% | — | ||
| Q1 25 | 9.9% | — | ||
| Q4 24 | 8.5% | — | ||
| Q3 24 | 6.8% | — | ||
| Q2 24 | 3.8% | — | ||
| Q1 24 | 8.0% | — |
| Q4 25 | $1.99 | — | ||
| Q3 25 | — | $1.33 | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-0.60 | ||
| Q2 24 | — | $-0.68 | ||
| Q1 24 | — | $-0.53 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $18.2M | $786.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $213.6M | $1.1B |
| Total Assets | $628.9M | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $18.2M | — | ||
| Q3 25 | $22.5M | $786.9M | ||
| Q2 25 | $19.4M | — | ||
| Q1 25 | $25.6M | — | ||
| Q4 24 | $26.7M | — | ||
| Q3 24 | $24.5M | $920.0M | ||
| Q2 24 | $24.6M | $701.7M | ||
| Q1 24 | $37.1M | $698.8M |
| Q4 25 | $213.6M | — | ||
| Q3 25 | $201.7M | $1.1B | ||
| Q2 25 | $197.0M | — | ||
| Q1 25 | $227.3M | — | ||
| Q4 24 | $212.1M | — | ||
| Q3 24 | $204.5M | $1.2B | ||
| Q2 24 | $191.7M | $931.7M | ||
| Q1 24 | $211.8M | $935.3M |
| Q4 25 | $628.9M | — | ||
| Q3 25 | $629.0M | $1.2B | ||
| Q2 25 | $606.8M | — | ||
| Q1 25 | $590.4M | — | ||
| Q4 24 | $571.4M | — | ||
| Q3 24 | $582.3M | $1.2B | ||
| Q2 24 | $546.0M | $973.7M | ||
| Q1 24 | $552.5M | $961.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $22.4M | $142.2M |
| Free Cash FlowOCF − Capex | — | $142.2M |
| FCF MarginFCF / Revenue | — | 68.4% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | 1.70× | 1.19× |
| TTM Free Cash FlowTrailing 4 quarters | — | $13.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $22.4M | — | ||
| Q3 25 | $36.5M | $142.2M | ||
| Q2 25 | $5.9M | — | ||
| Q1 25 | $-80.0M | — | ||
| Q4 24 | $79.4M | — | ||
| Q3 24 | $31.6M | $-49.2M | ||
| Q2 24 | $1.8M | $-32.9M | ||
| Q1 24 | $-63.1M | $-43.8M |
| Q4 25 | — | — | ||
| Q3 25 | $35.9M | $142.2M | ||
| Q2 25 | $4.7M | — | ||
| Q1 25 | $-81.0M | — | ||
| Q4 24 | $68.8M | — | ||
| Q3 24 | $28.6M | $-49.7M | ||
| Q2 24 | $-509.0K | $-33.9M | ||
| Q1 24 | $-63.8M | $-45.1M |
| Q4 25 | — | — | ||
| Q3 25 | 19.3% | 68.4% | ||
| Q2 25 | 2.5% | — | ||
| Q1 25 | -44.5% | — | ||
| Q4 24 | 39.0% | — | ||
| Q3 24 | 17.0% | — | ||
| Q2 24 | -0.3% | — | ||
| Q1 24 | -37.1% | — |
| Q4 25 | — | — | ||
| Q3 25 | 0.3% | 0.0% | ||
| Q2 25 | 0.6% | — | ||
| Q1 25 | 0.5% | — | ||
| Q4 24 | 6.0% | — | ||
| Q3 24 | 1.8% | — | ||
| Q2 24 | 1.4% | — | ||
| Q1 24 | 0.4% | — |
| Q4 25 | 1.70× | — | ||
| Q3 25 | 3.19× | 1.19× | ||
| Q2 25 | 0.48× | — | ||
| Q1 25 | -4.44× | — | ||
| Q4 24 | 5.30× | — | ||
| Q3 24 | 2.76× | — | ||
| Q2 24 | 0.28× | — | ||
| Q1 24 | -4.61× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
